Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Phase 2/3 Recruiting
596 enrolled
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Phase 2/3 Recruiting
1,260 enrolled
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
660 enrolled
CheckMate-1533
Phase 2 Recruiting
76 enrolled
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Phase 2/3 Recruiting
854 enrolled
A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 Recruiting
681 enrolled
INTerpath-009
Phase 3 Recruiting
680 enrolled
DL03
Phase 1 Recruiting
304 enrolled
PALOMA-2
Phase 2 Recruiting
520 enrolled
TroFuse-019
Phase 3 Recruiting
780 enrolled
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Phase 1 Recruiting
500 enrolled
eVOLVE-01
Phase 2 Recruiting
180 enrolled
TroFuse-020
Phase 3 Recruiting
686 enrolled
Krascendo 2
Phase 3 Recruiting
600 enrolled
KANDLELIT-007
Phase 3 Recruiting
675 enrolled
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Phase 2 Recruiting
130 enrolled
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Phase 3 Recruiting
630 enrolled
MountainTAP-29
Phase 2/3 Recruiting
590 enrolled
REZILIENT4
Phase 3 Recruiting
360 enrolled
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Phase 3 Recruiting
398 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Phase 1/2 Recruiting
434 enrolled
eVOLVE-Meso
Phase 3 Recruiting
825 enrolled
MK-2870-009
Phase 3 Recruiting
520 enrolled
Pan Tumor Rollover Study
Phase 2 Recruiting
1,500 enrolled
SOHO-02
Phase 3 Recruiting
444 enrolled
RELATIVITY1093
Phase 3 Recruiting
1,000 enrolled
MK-3475-01E
Phase 2 Recruiting
60 enrolled
ALTAIR
Phase 1/2 Recruiting
152 enrolled
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/2 Recruiting
370 enrolled
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
340 enrolled
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Phase 3 Recruiting
878 enrolled
SUNRAY-01
Phase 3 Recruiting
1,264 enrolled
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 Recruiting
387 enrolled
KRAScendo 170
Phase 1/2 Recruiting
320 enrolled
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Phase 1 Recruiting
321 enrolled
SYNERGY-101
Phase 1/2 Recruiting
364 enrolled
VELOCITY-Lung
Phase 2 Recruiting
270 enrolled
MK-3475-01A
Phase 1/2 Recruiting
450 enrolled
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Phase 1/2 Recruiting
442 enrolled
NeoCOAST-2
Phase 2 Recruiting
630 enrolled
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
Phase 3 Recruiting
726 enrolled
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/2 Recruiting
616 enrolled
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Phase 3 Recruiting
400 enrolled
TROPION-Lung15
Phase 3 Recruiting
744 enrolled
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Phase 1/2 Recruiting
252 enrolled
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
Phase 2 Recruiting
107 enrolled
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Phase 1 Recruiting
330 enrolled
LIVIGNO-4
Phase 2/3 Recruiting
840 enrolled
MK-3475-01G
Phase 2 Recruiting
90 enrolled